Filtered By:
Source: American Heart Journal
This page shows you your search results in order of relevance. This is page number 11.
Order by Relevance | Date
Total 491 results found since Jan 2013.
Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation
Conclusions Urinary 11-dehydro-TxB2 levels are associated with a residual risk of CVEs and CV mortality in patients with AF despite anticoagulant treatment.
Source: American Heart Journal - September 15, 2015 Category: Cardiology Source Type: research
Assessment of the Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at High-Risk for Vascular Outcomes – Rationale and Design of the ACCELERATE Trial
Conclusions ACCELERATE will establish whether the CETP inhibition by evacetrapib improves cardiovascular outcomes in patients with high risk vascular disease.
Source: American Heart Journal - September 16, 2015 Category: Cardiology Source Type: research
A Randomized Trial to Compare the Safety of Rivaroxaban versus Aspirin in Addition to Either Clopidogrel or Ticagrelor in Acute Coronary Syndrome: The Design of the GEMINI-ACS-1 Phase II Study
Publication date: Available online 18 January 2016 Source:American Heart Journal Author(s): Thomas J. Povsic, Matthew T. Roe, E. Magnus Ohman, Philippe Gabriel Steg, Stefan James, Alexei Plotnikov, Hardi Mundl, Robert Welsh, Christoph Bode, C. Michael Gibson Dual antiplatelet therapy (DAPT), the combination of aspirin and a P2Y12 inhibitor, given for 12 months remains the standard of care after presentation with acute coronary syndrome (ACS) because it has been shown to be associated with a significant reduction in ischemic events compared with aspirin monotherapy. The factor Xa inhibitor rivaroxaban was shown ...
Source: American Heart Journal - January 19, 2016 Category: Cardiology Source Type: research
Design and Rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) Trial
Conclusions The EUCLID study is investigating whether treatment with ticagrelor versus clopidogrel, given as antiplatelet monotherapy, will reduce the incidence of cardiovascular and limb-specific events in patients with symptomatic PAD.
Source: American Heart Journal - January 30, 2016 Category: Cardiology Source Type: research
Cardiovascular health among diverse Hispanics/Latinos: Hispanic Community Health Study/Study of Latinos Results
Conclusions Hispanic/Latino LS7s compared favorably with existing national estimates; however, we found areas for improvement. Several Hispanic/Latino LS7 strengths and weaknesses varied by sex and heritage, providing important information to guide targeted health promotion efforts toward achieving 2020 goals.
Source: American Heart Journal - February 20, 2016 Category: Cardiology Source Type: research
A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study
Publication date: April 2016 Source:American Heart Journal, Volume 174 Author(s): Thomas J. Povsic, Matthew T. Roe, Erik Magnus Ohman, Philippe Gabriel Steg, Stefan James, Alexei Plotnikov, Hardi Mundl, Robert Welsh, Christoph Bode, Charles Michael Gibson Dual antiplatelet therapy (DAPT), the combination of aspirin and a P2Y12 inhibitor, given for 12 months remains the standard of care after presentation with acute coronary syndrome (ACS) because it has been shown to be associated with a significant reduction in ischemic events compared with aspirin monotherapy. The factor Xa inhibitor rivaroxaban was shown to ...
Source: American Heart Journal - February 23, 2016 Category: Cardiology Source Type: research
A clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT AF): design and rationale
The objective of this prospective, cluster randomized controlled trial (IMPACT-AF; ClinicalTrials.gov #NCT02082548) is to determine whether a comprehensive customized intervention will increase the rate and persistence of use of OAC in patients with AF. IMPACT-AF will be conducted in approximately 50 centers in 5 low- to middle-income countries. Before randomization, sites within countries will be paired to match in size, practice type and baseline rate of OAC use. Site pairs will be randomized to intervention versus control. In total, 40 to 70 patients with AF and at least 2 CHA2DS2-VASc risk factors will be enrolled at e...
Source: American Heart Journal - March 21, 2016 Category: Cardiology Source Type: research
A comparison of the CHARGE-AF and the CHA2DS2-VASc risk scores for prediction of atrial fibrillation in the Framingham Heart Study
Conclusion The CHARGE-AF risk score performed better than the CHA2DS2-VASc risk score at predicting AF in a community-based cohort.
Source: American Heart Journal - May 16, 2016 Category: Cardiology Source Type: research
A comparison of the CHARGE–AF and the CHA2DS2-VASc risk scores for prediction of atrial fibrillation in the Framingham Heart Study
Conclusion The CHARGE-AF risk score performed better than the CHA2DS2-VASc risk score at predicting AF in a community-based cohort.
Source: American Heart Journal - May 31, 2016 Category: Cardiology Source Type: research
Effect of Age on Efficacy and Safety of Vorapaxar in Patients with Non–ST-Segment Elevation Acute Coronary Syndrome: Insights from the TRACER Trial
Conclusion Older patients had a greater risk for ischemic and bleeding events; however, the efficacy and safety of vorapaxar in NSTE ACS were not significantly influenced by age.
Source: American Heart Journal - June 8, 2016 Category: Cardiology Source Type: research
Complete Versus Incomplete Revascularization in Patients with Multivessel Coronary Artery Disease Treated With Drug-Eluting Stents
Conclusions Among patients with multivessel CAD treated with DES, as compared with CR, IR was associated with similar risk of death. However, IR was associated with a higher risk of MI during follow-up.
Source: American Heart Journal - July 7, 2016 Category: Cardiology Source Type: research
A comparison of the CHARGE –AF and the CHA2DS2-VASc risk scores for prediction of atrial fibrillation in the Framingham Heart Study
Conclusion The CHARGE-AF risk score performed better than the CHA2DS2-VASc risk score at predicting AF in a community-based cohort.
Source: American Heart Journal - July 20, 2016 Category: Cardiology Source Type: research
Effect of age on efficacy and safety of vorapaxar in patients with non –ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial
Conclusion Older patients had a greater risk for ischemic and bleeding events; however, the efficacy and safety of vorapaxar in NSTE ACS were not significantly influenced by age.
Source: American Heart Journal - July 20, 2016 Category: Cardiology Source Type: research
Rationale and design of the Transcatheter Aortic Valve Replacement to UNload the Left ventricle in patients with ADvanced heart failure (TAVR UNLOAD) trial
Publication date: Available online 26 August 2016 Source:American Heart Journal Author(s): Ernest Spitzer, Nicolas M. Van Mieghem, Philippe Pibarot, Rebecca T. Hahn, Susheel Kodali, Mathew S. Maurer, Tamim M. Nazif, Josep Rodés-Cabau, Jean-Michel Paradis, Arie-Pieter Kappetein, Ori Ben-Yehuda, Gerrit-Anne van Es, Faouzi Kallel, William N. Anderson, Jan Tijssen, Martin B. Leon Background Co-existence of moderate aortic stenosis (AS) in patients with heart failure with reduced ejection fraction (HFrEF) is not uncommon. Moderate AS increases afterload, while pharmacological reduction of afterload is a pillar of contemporary...
Source: American Heart Journal - August 26, 2016 Category: Cardiology Source Type: research
Atorvastatin for High Risk Statin-Na ïve Patients Undergoing Noncardiac Surgery: The LOAD Randomized Trial
Conclusion In contrast to the prior observational and trial data, the LOAD trial has neutral results and did not demonstrate a reduction in major cardiovascular complications after a short-term perioperative course of statin in statin-naïve patients undergoing non-cardiac surgery. We demonstrated, however, that a large multicenter blinded perioperative statin trial for high risk statin-naïve patients is feasible, and should be done to definitely establish the efficacy and safety of statin in this patient population. Clinical trial registration: Clinicaltrials.gov Identifier: NCT01543555
Source: American Heart Journal - November 9, 2016 Category: Cardiology Source Type: research
